DRI Healthcare Trust (TSE:DHT.UN) Given Consensus Rating of “Moderate Buy” by Brokerages

DRI Healthcare Trust (TSE:DHT.UN) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is C$17.94.

Several brokerages have issued reports on DHT.UN. CIBC cut their price target on DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating on the stock in a report on Thursday, December 12th. Scotiabank increased their price target on DRI Healthcare Trust from C$21.00 to C$22.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Finally, Raymond James cut their price target on DRI Healthcare Trust from C$23.00 to C$22.00 in a report on Wednesday, November 13th.

DRI Healthcare Trust Stock Down 0.7 %

TSE DHT.UN opened at C$12.25 on Friday. The business has a 50 day simple moving average of C$12.26 and a 200 day simple moving average of C$12.57. DRI Healthcare Trust has a one year low of C$10.39 and a one year high of C$17.43.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.